With more than 30 years of global biopharmaceutical leadership experience, Pascal Touchon joined Atara Biotherapeutics as President, Chief Executive Officer and member of the Board of Directors in June 2019. Pascal has committed his career to transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence.
Previously Global Head, Cell & Gene and member of the Oncology Executive Committee at Novartis Oncology, he oversaw the Oncology Cell & Gene unit and had responsibility for the unit’s financial performance and its activities, including the global launch of KYMRIAH® (tisagenlecleucel), securing regulatory approval and reimbursement in major markets, expanding global CAR T manufacturing and technical operations, overseeing multiple new clinical studies, and building a strong leadership team.
Prior to that, he served as Global Head, Strategy, Business Development, Oncology at Novartis, where he was responsible for early commercial strategy, portfolio management, therapeutic integrity and established medicines, disruptive technologies, diagnostics, business development and external collaborations, and served as a member of the Oncology Executive Committee. Pascal has also held key leadership roles in research, marketing, general management, and business development at companies including Servier, Glaxo-Wellcome and Glaxo, Sanofi. He has also been a board member of Genoptix and Navigate Biopharma Services (Novartis companies) and Cogen Therapeutics (a Flagship Pioneering company).
Pascal holds a doctorate in veterinary medicine from Paul Sabatier University (Toulouse, France), a Diplôme d’Etudes Superieures Specialisees (DESS) in management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).
Beyond his passion for science and business, Pascal enjoys traveling with his family around the world, wine tasting with friends, watching rugby, and reading.
What is Pascal Touchon's net worth?
The estimated net worth of Pascal Touchon is at least $1.37 million as of March 4th, 2024. Dr. Touchon owns 1,910,652 shares of Atara Biotherapeutics stock worth more than $1,365,543 as of April 25th. This net worth evaluation does not reflect any other investments that Dr. Touchon may own. Additionally, Dr. Touchon receives an annual salary of $1,080,000.00 as CEO at Atara Biotherapeutics. Learn More about Pascal Touchon's net worth.
How old is Pascal Touchon?
What is Pascal Touchon's salary?
How do I contact Pascal Touchon?
Has Pascal Touchon been buying or selling shares of Atara Biotherapeutics?
Pascal Touchon has not been actively trading shares of Atara Biotherapeutics within the last three months. Most recently, Pascal Touchon sold 24,844 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $0.72, for a transaction totalling $17,887.68. Following the completion of the sale, the chief executive officer now directly owns 1,910,652 shares of the company's stock, valued at $1,375,669.44. Learn More on Pascal Touchon's trading history.
Who are Atara Biotherapeutics' active insiders?
Are insiders buying or selling shares of Atara Biotherapeutics?
During the last year, Atara Biotherapeutics insiders bought shares 2 times. They purchased a total of 279,020 shares worth more than $64,384.40. During the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 184,801 shares worth more than $237,993.35. The most recent insider tranaction occured on March, 4th when CEO Pascal Touchon sold 24,844 shares worth more than $17,887.68. Insiders at Atara Biotherapeutics own 4.5% of the company.
Learn More about insider trades at Atara Biotherapeutics. Information on this page was last updated on 3/4/2024.
